"Cytochrome P-450 CYP2C19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.
| Descriptor ID |
D065731
|
| MeSH Number(s) |
D08.244.453.491.500.700 D08.811.682.690.708.170.450.500.700 D12.776.422.220.453.491.500.700
|
| Concept/Terms |
Cytochrome P-450 CYP2C19- Cytochrome P-450 CYP2C19
- CYP2C19, Cytochrome P-450
- Cytochrome P 450 CYP2C19
- P-450 CYP2C19, Cytochrome
- CYPIIC19
- S-Mephenytoin 4'-Hydroxylase
- 4'-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4' Hydroxylase
- CYP2C19
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C19".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C19".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C19" by people in this website by year, and whether "Cytochrome P-450 CYP2C19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 4 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 3 | 5 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C19" by people in Profiles.
-
Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and phenoconversion in 15,000 patients. Mol Psychiatry. 2024 Nov; 29(11):3495-3502.
-
Human CYP2C19 Substrate and Inhibitor Characterization of Organophosphate Pesticides. Chem Res Toxicol. 2023 09 18; 36(9):1451-1455.
-
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. J Mol Diagn. 2022 04; 24(4):337-350.
-
CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant
Strain of Helicobacter pylori Infection Asian Pac J Cancer Prev. 2019 Apr 29; 20(4):1243-1247.
-
Multisite Investigation of Outcomes With?Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 01 22; 11(2):181-191.
-
Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
-
Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype. Helicobacter. 2016 Apr; 21(2):85-90.
-
Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2015; 9(12):1535-47.
-
Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015; 19(12):1637-50.
-
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. Ann Am Thorac Soc. 2015 Jun; 12(6):878-85.